As of November 6, 2026, XOMA Royalty Corp has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on July 14, 2026 (Form 8-K, July 14, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like XOMA Royalty Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
XOMA Royalty Corp reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-07-14. Every row below is cited to the filing it comes from, and this page adds each new change as XOMA Royalty Corp files it.
Also on the record for XOMA Royalty Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 7, 2026 | Stake report, Schedule 13G/A, by FMR LLC | — | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G/A, by Morgan Stanley | 9.5% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G/A, by Morgan Stanley | — | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 9.1% of the class | 5%+ stakes | Source |
| July 31, 2026 | Stake report, Schedule 13G/A, by Vanguard Capital Management | 3.23% of the class | 5%+ stakes | Source |
| July 30, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 3.9% of the class | 5%+ stakes | Source |
| July 16, 2026 | Stake report, Schedule 13D/A, by BIOTECHNOLOGY VALUE FUND L P | — | 5%+ stakes | Source |
| May 18, 2026 | Stake report, Schedule 13D/A, by BIOTECHNOLOGY VALUE FUND L P | 43.3% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Woodline Partners LP | 5.4% of the class | 5%+ stakes | Source |
| May 1, 2026 | Stake report, Schedule 13D, by Ligand Pharmaceuticals Incorporated | 47% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.15% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13D/A, by BIOTECHNOLOGY VALUE FUND L P | 21.4% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs XOMA Royalty Corp now and the warning signs.
Free to see. No signup.
Keep reading
More on XOMA Royalty Corp and the records around it.
XOMA Royalty Corp elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Ligand Pharmaceuticals Incorporated also filed stake reports on 1 other company: Pelthos Therapeutics Inc. (Nov 2026)
- Woodline Partners LP also filed stake reports on 19 other companies: Biohaven Ltd. (Aug 2026), Black Rock Coffee Bar, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
Watch XOMA Royalty Corp
Get an email when XOMA Royalty Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on XOMA Royalty Corp?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on XOMA Royalty Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on XOMA Royalty Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 20 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-14 | Reported | not named in the filing | 8-K, 2026-07-14 |
New leaders reset buying decisions — get the Full Report on XOMA Royalty Corp: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at XOMA Royalty Corp, with the record behind each one.
Find candidates like senior executive at XOMA Royalty CorpEvery change, in the filing's words
Reported
In accordance with the terms of the Merger Agreement, effective as of the Effective Time, (i) the directors of Merger Sub as of immediately prior to the Effective Time, Todd C. Davis, Octavio Espinoza and Andrew Reardon, became the directors of the Company until the earlier of their resignation or removal or until their respective successors are duly designated, as the case may be, and each of Jack L. Wyszomierski, Heather L. Franklin, Natasha Hernday, Owen Hughes, Barbara Kosacz, Joseph M. Limber and Matthew Perry, voluntarily resigned as directors of the Company and from all committees of th
Tools for this story
Each opens in a new tab, filled in for XOMA Royalty Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.